Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 87.42M -62.5% |
| Revenue (ttm) | n/a |
| Net Income | -101.90M |
| EPS | -6.09 |
| Shares Out | 19.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,065,287 |
| Open | 4.350 |
| Previous Close | 4.330 |
| Day's Range | 4.220 - 4.720 |
| 52-Week Range | 4.220 - 20.560 |
| Beta | 2.63 |
| Analysts | Strong Buy |
| Price Target | 34.03 (+652.88%) |
| Est. Earnings | Nov 11, 2026 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price target is $34.03, which is an increase of 652.88% from the latest price.
News
Corbus announces first patient dosed in TEMPO-1 study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate, in second-lin...
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with ...
Corbus Pharmaceuticals Holdings Transcript: Study result
CANYON-1 phase I-B results show CRB-913, a peripherally restricted CB1 inverse agonist, achieved 5% placebo-adjusted weight loss in 12 weeks with a favorable safety profile and no severe psychiatric or GI events. Efficacy was comparable to oral GLP-1s, supporting further development and combination potential.
Corbus Pharmaceuticals Holdings Press release: Study result
Corbus Pharmaceuticals Holdings issued a press release on September 14, 2026, disclosing material business information to investors.
Corbus Pharmaceuticals Holdings Slides: Study result
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Corbus Pharmaceuticals announces topline data from CANYON-1 trial
Corbus Pharmaceuticals (CRBP) announced topline data from the company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The data demonstrated statistically significant and cl...
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric a...
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the g...
Corbus Pharmaceuticals price target lowered to $33 from $34 at Mizuho
Mizuho lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $33 from $34 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Corbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer
Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $48 from $52 and keeps an Outperform rating on the shares following quarterly results and business update. Promising res...
Corbus Pharmaceuticals Holdings Earnings release: Q2 2026
Corbus Pharmaceuticals Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Corbus Pharmaceuticals Holdings Quarterly report: Q2 2026
Corbus Pharmaceuticals Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Corbus reports last patient completes last visit in CANYON-1 trial
Corbus Pharmaceuticals (CRBP) announced the last patient has completed their last clinical visit in the company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1...
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 ...
Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
Corbus Pharmaceuticals (CRBP) announced that the FDA has cleared the start of the company’s registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate, in second-line...
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patient...
Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer
Corbus Pharmaceuticals (CRBP) announced the appointment of Leonardo Viana Nicacio as chief medical officer. Prior to joining Corbus, he was the chief medical officer at Protara Therapeutics. Published...
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapi...
Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $34 from $44 and keeps an Outperform rating on the shares. The firm updated its revenue…
Corbus Pharmaceuticals Holdings Slides: Corporate presentation
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $52 from $54 and keeps an Outperform rating on the shares. The firm recently hosted a lively investor dinner…
Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026
Two lead clinical assets are advancing: CRB-701 shows strong efficacy in HPV-positive oropharyngeal and cervical cancers, with pivotal studies aligned with FDA and a significant U.S. market opportunity. CRB-913 obesity data is expected in September, and cash runway extends into 2028.
Corbus Pharmaceuticals Holdings Slides: FY 2026
Corbus Pharmaceuticals Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Corbus Pharmaceuticals Holdings Transcript: KOL event
Panelists highlighted the rising incidence and unmet need in HPV-positive oropharyngeal cancer, emphasizing the promise of Nectin-4 ADCs like CRB-701 for this motivated patient group. Strategic trial design, manageable toxicity, and focused site selection are expected to drive rapid enrollment and strong clinical impact.